Bioactive renal cells for the treatment of chronic kidney disease

1. A method for reducing rate of increase in serum creatinine (sCr) in the treatment of chronic kidney disease (CKD) in a human patient comprising an estimated glomerular filtration rate of 15 to 60 mL/min, the method comprising:

injecting into the renal cortex of at least one kidney of the patient having said CKD a composition comprising 1.0-9.0×10 6 cells of a selected renal cell (SRC) population per gram estimated kidney weight (/gKW est )

wherein the SRC population is enriched for renal tubular cells and exhibits a buoyant density greater than approximately 1.0419 g/mL; and

thereby reducing the rate of increase in sCr of the human patient.

2. The method of claim 1 , wherein the injection is performed using a minimally invasive procedure such as percutaneous, laparoscopic or intravascular procedures.

3. The method of claim 1 , wherein a guiding cannula inserted percutaneously is used to puncture the kidney capsule prior to injection of the composition into the kidney of the patient.

4. The method of claim 1 , wherein the composition is administered with a minimum of one injection in one kidney.

5. The method of claim 1 , wherein the composition is administered as two or more injections.

6. The method of claim 5 , wherein a second of the two or more injections is administered any time up to 3 years after the first injection.

7. The method of claim 1 , wherein the composition is administered to the patient who is contemporaneously receiving standard-of-care treatment for CKD prior to receiving injections of the composition.

8. The method of claim 1 , wherein the composition is injected into one kidney of the patient.

9. The method of claim 1 , wherein the composition is injected into both kidneys of the patient.

10. The method of claim 1 , wherein the injection is into the renal parenchyma.

11. The method of claim 1 , wherein the composition injected to the renal cortex of the at least one kidney comprises 3×10 6 SRC/g KW est .

12. The method of claim 1 , wherein the SRC population exhibits the buoyant density greater than approximately 1.0419 g/mL following density gradient separation.

13. The method of claim 1 , wherein the reducing the rate of increase in sCr of the human patient is by at least 50%.

14. The method of claim 1 , wherein the reducing rate of increase in sCr of the human patient is achieved following a single first injecting step.

15. A method for delaying dialysis in the treatment of chronic kidney disease in a human patient comprising an estimated glomerular filtration rate of 15 to 60 mL/min, the method comprising:

injecting into the renal cortex of at least one kidney of the patient having said CKD a composition comprising 1.0-9.0×10 6 cells of a selected renal cell (SRC) population per gram estimated kidney weight (/gKW est ),

wherein the SRC population is enriched for renal tubular cells and exhibits a buoyant density greater than approximately 1.0419 g/mL;

thereby delaying dialysis of the human patient.

16. The method of claim 15 , wherein the SRC population exhibits the buoyant density greater than approximately 1.0419 g/mL following density gradient separation.

17. The method of claim 15 , wherein the composition injected to the renal cortex of the at least one kidney comprises 3×10 6 SRC/g KW est .

18. The method of claim 15 , wherein the injection is performed using a minimally invasive procedure such as percutaneous, laparoscopic or intravascular procedures.

19. The method of claim 15 , wherein the delaying dialysis of the human patient is by at least 1.5 years.

20. The method of claim 19 , wherein the delaying dialysis is achieved following a single first injecting step.